Our investors
A team of highly experienced industry experts
Azafaros is supported by a syndicate of leading Dutch and Swiss investors. Our clinical candidate AZ-3102 is an orally available azasugar designed to treat the central nervous system and to interfere with the metabolism of glycosphingolipids affecting key disease pathways through a unique dual mode of action.
Azafaros aims to be a beacon for patients living with severe rare genetic diseases and their families.
– Since 2018